BusinessAgile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive MedicineBy Nasdaq OMXSep 7, 2017, 11:50 AM UTC
BusinessAgile Therapeutics Announces Pricing of Its Public Offering of Common StockBy Nasdaq OMXAug 3, 2017, 12:24 PM UTC
BusinessAgile Therapeutics Reports Second Quarter 2017 Financial ResultsBy Nasdaq OMXJul 28, 2017, 11:30 AM UTC
BusinessAgile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®By Nasdaq OMXJul 27, 2017, 8:12 PM UTC
BusinessAgile Therapeutics Reports First Quarter 2017 Financial ResultsBy Nasdaq OMXMay 8, 2017, 8:11 PM UTC
BusinessAgile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s HealthBy Nasdaq OMXApr 27, 2017, 11:31 AM UTC
BusinessITL Pharma Receives United States Patent Protection for TriThroid® Using Sustained Drug Release and Improved Product StabilityBy Nasdaq OMXFeb 14, 2017, 2:10 PM UTC
